Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 535-541

  Kim, Hee Man ^a   Bang, Seungmin ^a   Park, Jeong Youp ^b   Seong, Jinsil ^a   Song, Si Young ^a   Chung, Jae Bock ^a   Park, Seung Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Inha University   (South Korea)

Author keywords

Concurrent chemoradiotherapy; Locally advanced; Pancreatic cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HISTOLOGY; HUMAN; LEUKOPENIA; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ULCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; DISEASE COURSE; DRUG COMBINATION; MIDDLE AGED; PANCREAS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 58249132914     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0836-1     Document Type: Article

References (32)

1. RP A'Hern 2001 Sample size table for exact single-stage phase II designs Stat Med 20 859 866 (Pubitemid 32249085)
2. S Bang HW Chung SW Park JB Chung M Yun JD Lee SY Song 2006 The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer J Clin Gastroenterol 40 923 929
3. HA Burris MJ Moore J Anderson MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 (Pubitemid 27251144)
4. HJ Choi NK Kim KC Keum SH Cheon SJ Shin SH Baik JH Choen SY Rha JK Roh HC Jeung HC Chung JB Ahn 2008 Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer Radiother Oncol 87 361 366
5. CH Crane G Varadhachary PWT Pisters DB Evans RA Wolff 2007 Future chemoradiation strategies in pancreatic cancer Semin Oncol 34 335 346 (Pubitemid 47176616)
6. Gastrointestinal Tumor Study Group 1988 Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radioatherapy) to chemotherapy alone J Natl Cancer Inst 80 751 755 (Pubitemid 18180650)
7. K Harada T Ferdous H Yoshida 2007 Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma Oncol Rep 18 1077 1083
8. K Harada S Kawaguchi Supriatno Y Kawashima H Yoshida M Sato 2005 S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB Cancer Lett 226 161 168 (Pubitemid 41039084)
9. K Harada S Kawaguchi Supriatno T Onoue H Yoshida M Sato 2004 Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells Oral Oncol 40 713 719 (Pubitemid 38686908)
10. K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki Y Nakano H Ishizuka Y Yamada S Uno T Taguchi T Shirasaka 1995 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000 2005 (Pubitemid 29399250)
11. F Huguet T André P Hammel P Artru J Balosso F Selle E Deniaud-Alexandre P Ruszniewski E Touboul R Labianca A de Gramont C Louvet 2007 Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 326 331 (Pubitemid 350003022)
12. M Ikeda T Okusaka Y Ito H Ueno C Morizane F Furuse H Ishii M Kawashima Y Kagami H Ikeda 2007 A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer Br J Cancer 96 1650 1655 (Pubitemid 46847209)
13. H Ishii J Furuse K Nakachi E Suzuki M Yoshino 2005 Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials Jpn J Clin Oncol 35 601 606 (Pubitemid 41662697)
14. R Kim MW Saif 2007 Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? J Pancreas 8 279 288 (Pubitemid 46876786)
15. Y Kimura N Kikkawa S Iijima T Kato Y Naoi T Hayashi T Tanigawa H Yamamoto E Kurokawa 2003 A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice Gastric Cancer 6 Suppl 1 34 39 (Pubitemid 36604654)
16. DJ Klaassen JM [tmp] MacIntyre GE Catton PF Engstrom CG Moertel 1985 Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study J Clin Oncol 3 373 378 (Pubitemid 15132005)
17. TS Lawrence EY Chang TM Hahn LW Hertel DS Shewach 1996 Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine Int J Radiat Oncol Biol Phys 34 867 872
18. CG Moertel DS Childs Jr RJ Reitemeier MY Colby Jr MA Holbrook 1969 Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer Lancet 2 865 867
19. CG Moertel S Frytak RG Hahn MJ O'Connell RJ Reitemeier J Rubin AJ Schutt LH Weiland DS Childs MA Holbrook PT Lavin E Livstone H Spiro A Knowlton M Kalser J Barkin H Lessner R Mann-Kaplan K Ramming HO Douglas Jr P Thomas H Nave J Bateman J Lokich J Brooks J Chaffey JM Corson N Zamcheck JW Novak 1981 Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1705 1710 (Pubitemid 11022870)
20. L Moureau-Zabotto JM Phélip P Afchain L Mineur T André V Vendrely G Lledo O Dupuis F Huguet E Touboul J Balosso C Louvet 2008 Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study J Clin Oncol 26 1080 1085
21. E Nakata M Fukushima Y Takai K Nemoto Y Ogawa T Nomiya Y Nakamura L Milas S Yamada 2006 S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU Oncol Rep 16 465 471
22. A Ohtsu H Baba Y Sakata Y Mitachi N Horikoshi K Sugimachi T Taguchi 2000 Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma Br J Cancer 83 141 145 (Pubitemid 30411708)
23. T Okusaka A Funakoshi J Furuse N Boku K Yamao S Ohkawa H Saito 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621
24. N Oya 2004 Chemoradiotherapy for pancreatic cancer: current status and perspectives Int J Clin Oncol 9 451 457
25. A Sultana C Tudur Smith D Cunningham N Starling JP Neoptolemos P Ghaneh 2008 Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses Br J Cancer 99 6 13
26. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 (Pubitemid 28474225)
27. H Shinchi K Maemura H Noma Y Mataki T Aikou S Takao 2007 Phase-I trial of oral fluoropyridine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer Br J Cancer 96 1353 1357 (Pubitemid 46685793)
28. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotocitiy of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 (Pubitemid 26276346)
29. K Sudo T Yamaguchi T Ishihara K Nakamura Y Shirai N Akihiko H Kawakami T Uno H Ito H Saisho 2007 Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer Int J Radiation Oncology Biol Phys 67 219 224
30. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
31. H Tsuji T Kiba M Nagata T Inoue H Yukawa T Yamashita Y Shimode H Murata K Nagata K Tomoda 2006 A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma Oncology 71 369 373
32. H Ueno T Okusaka M Ikeda Y Takezako 2005 An early phase II study of S-1 in patients with metastatic pancreatic cancer Oncology 68 171 178 (Pubitemid 41158973)